Non-linear pharmacokinetics of sparteine in the rat

M Van der Graaff, N P Vermeulen, M C Koperdraat, D D Breimer

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

In rats, blood concentrations of sparteine (SP) and relative concentrations of sodium borohydride-reducible metabolite following intra-arterial (i.a.) and portal venous administration of SP-sulphate were estimated up to 200 min. In 24 hr urine, unchanged SP was quantitated. Borohydride-reducible metabolite was measured as the difference in SP concentrations before and after reduction. Administration of SP in a dose of 50 mg/kg SP-sulphate i.a. revealed a blood concentration-time profile which did not allow characterization of the terminal half-life or systemic clearance. Therefore, the dose over the area under the curve up to 120 min after administration, CL0-120app, was defined as an apparent average clearance value over the time interval studied. After a dose of 50 mg/kg the CL0-120app was 34.8 +/- 5.9 ml/min/kg when administered i.a. and 80.4 +/- 7.5 ml/min/kg when administered via the portal vein, thus affording an estimate of 0.64 +/- 0.12 for the hepatic extraction ratio. A possible biliary excretion and enterohepatic circulation was studied in rats with a bile fistula. Although SP levels in blood were lower than in control rats, no SP was excreted in the bile and excretion of SP in urine was even slightly higher, which renders circulation of SP itself unlikely. About 25% of the dose was recovered in 180 min bile as borohydride-reducible metabolite, but the urinary excretion of borohydride-reducible metabolite was not changed. The gradual levelling-off of blood concentration versus time curves may partly be explained by the formation of reactive intermediates in the course of metabolism, which inactivate P-450. In support of this, the intrinsic clearance of orally administered hexobarbital (25 mg/kg) was determined 5 and 50 min after i.a. administered SP-sulphate (50 mg/kg), and decreased from 343 +/- 18 to 220 +/- 36 ml/min/kg (p less than 0.05).

Original languageEnglish
Pages (from-to)181-95
Number of pages15
JournalArchives internationales de pharmacodynamie et de therapie
Volume282
Issue number2
Publication statusPublished - Aug 1986

Fingerprint

Sparteine
Pharmacokinetics
Borohydrides
Bile
Urine
Enterohepatic Circulation
Hexobarbital
Portal Vein
Area Under Curve
Fistula
Half-Life

Keywords

  • Animals
  • Bile
  • Bile Ducts
  • Carotid Arteries
  • Catheterization
  • Chromatography, Gas
  • Kinetics
  • Male
  • Portal Vein
  • Rats
  • Rats, Inbred Strains
  • Sparteine
  • Journal Article

Cite this

Van der Graaff, M ; Vermeulen, N P ; Koperdraat, M C ; Breimer, D D. / Non-linear pharmacokinetics of sparteine in the rat. In: Archives internationales de pharmacodynamie et de therapie. 1986 ; Vol. 282, No. 2. pp. 181-95.
@article{7571423a0a82417388bce15de3cd55e2,
title = "Non-linear pharmacokinetics of sparteine in the rat",
abstract = "In rats, blood concentrations of sparteine (SP) and relative concentrations of sodium borohydride-reducible metabolite following intra-arterial (i.a.) and portal venous administration of SP-sulphate were estimated up to 200 min. In 24 hr urine, unchanged SP was quantitated. Borohydride-reducible metabolite was measured as the difference in SP concentrations before and after reduction. Administration of SP in a dose of 50 mg/kg SP-sulphate i.a. revealed a blood concentration-time profile which did not allow characterization of the terminal half-life or systemic clearance. Therefore, the dose over the area under the curve up to 120 min after administration, CL0-120app, was defined as an apparent average clearance value over the time interval studied. After a dose of 50 mg/kg the CL0-120app was 34.8 +/- 5.9 ml/min/kg when administered i.a. and 80.4 +/- 7.5 ml/min/kg when administered via the portal vein, thus affording an estimate of 0.64 +/- 0.12 for the hepatic extraction ratio. A possible biliary excretion and enterohepatic circulation was studied in rats with a bile fistula. Although SP levels in blood were lower than in control rats, no SP was excreted in the bile and excretion of SP in urine was even slightly higher, which renders circulation of SP itself unlikely. About 25{\%} of the dose was recovered in 180 min bile as borohydride-reducible metabolite, but the urinary excretion of borohydride-reducible metabolite was not changed. The gradual levelling-off of blood concentration versus time curves may partly be explained by the formation of reactive intermediates in the course of metabolism, which inactivate P-450. In support of this, the intrinsic clearance of orally administered hexobarbital (25 mg/kg) was determined 5 and 50 min after i.a. administered SP-sulphate (50 mg/kg), and decreased from 343 +/- 18 to 220 +/- 36 ml/min/kg (p less than 0.05).",
keywords = "Animals, Bile, Bile Ducts, Carotid Arteries, Catheterization, Chromatography, Gas, Kinetics, Male, Portal Vein, Rats, Rats, Inbred Strains, Sparteine, Journal Article",
author = "{Van der Graaff}, M and Vermeulen, {N P} and Koperdraat, {M C} and Breimer, {D D}",
year = "1986",
month = "8",
language = "English",
volume = "282",
pages = "181--95",
journal = "Archives internationales de pharmacodynamie et de therapie",
issn = "0003-9780",
publisher = "Wiley-Blackwell",
number = "2",

}

Van der Graaff, M, Vermeulen, NP, Koperdraat, MC & Breimer, DD 1986, 'Non-linear pharmacokinetics of sparteine in the rat' Archives internationales de pharmacodynamie et de therapie, vol. 282, no. 2, pp. 181-95.

Non-linear pharmacokinetics of sparteine in the rat. / Van der Graaff, M; Vermeulen, N P; Koperdraat, M C; Breimer, D D.

In: Archives internationales de pharmacodynamie et de therapie, Vol. 282, No. 2, 08.1986, p. 181-95.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Non-linear pharmacokinetics of sparteine in the rat

AU - Van der Graaff, M

AU - Vermeulen, N P

AU - Koperdraat, M C

AU - Breimer, D D

PY - 1986/8

Y1 - 1986/8

N2 - In rats, blood concentrations of sparteine (SP) and relative concentrations of sodium borohydride-reducible metabolite following intra-arterial (i.a.) and portal venous administration of SP-sulphate were estimated up to 200 min. In 24 hr urine, unchanged SP was quantitated. Borohydride-reducible metabolite was measured as the difference in SP concentrations before and after reduction. Administration of SP in a dose of 50 mg/kg SP-sulphate i.a. revealed a blood concentration-time profile which did not allow characterization of the terminal half-life or systemic clearance. Therefore, the dose over the area under the curve up to 120 min after administration, CL0-120app, was defined as an apparent average clearance value over the time interval studied. After a dose of 50 mg/kg the CL0-120app was 34.8 +/- 5.9 ml/min/kg when administered i.a. and 80.4 +/- 7.5 ml/min/kg when administered via the portal vein, thus affording an estimate of 0.64 +/- 0.12 for the hepatic extraction ratio. A possible biliary excretion and enterohepatic circulation was studied in rats with a bile fistula. Although SP levels in blood were lower than in control rats, no SP was excreted in the bile and excretion of SP in urine was even slightly higher, which renders circulation of SP itself unlikely. About 25% of the dose was recovered in 180 min bile as borohydride-reducible metabolite, but the urinary excretion of borohydride-reducible metabolite was not changed. The gradual levelling-off of blood concentration versus time curves may partly be explained by the formation of reactive intermediates in the course of metabolism, which inactivate P-450. In support of this, the intrinsic clearance of orally administered hexobarbital (25 mg/kg) was determined 5 and 50 min after i.a. administered SP-sulphate (50 mg/kg), and decreased from 343 +/- 18 to 220 +/- 36 ml/min/kg (p less than 0.05).

AB - In rats, blood concentrations of sparteine (SP) and relative concentrations of sodium borohydride-reducible metabolite following intra-arterial (i.a.) and portal venous administration of SP-sulphate were estimated up to 200 min. In 24 hr urine, unchanged SP was quantitated. Borohydride-reducible metabolite was measured as the difference in SP concentrations before and after reduction. Administration of SP in a dose of 50 mg/kg SP-sulphate i.a. revealed a blood concentration-time profile which did not allow characterization of the terminal half-life or systemic clearance. Therefore, the dose over the area under the curve up to 120 min after administration, CL0-120app, was defined as an apparent average clearance value over the time interval studied. After a dose of 50 mg/kg the CL0-120app was 34.8 +/- 5.9 ml/min/kg when administered i.a. and 80.4 +/- 7.5 ml/min/kg when administered via the portal vein, thus affording an estimate of 0.64 +/- 0.12 for the hepatic extraction ratio. A possible biliary excretion and enterohepatic circulation was studied in rats with a bile fistula. Although SP levels in blood were lower than in control rats, no SP was excreted in the bile and excretion of SP in urine was even slightly higher, which renders circulation of SP itself unlikely. About 25% of the dose was recovered in 180 min bile as borohydride-reducible metabolite, but the urinary excretion of borohydride-reducible metabolite was not changed. The gradual levelling-off of blood concentration versus time curves may partly be explained by the formation of reactive intermediates in the course of metabolism, which inactivate P-450. In support of this, the intrinsic clearance of orally administered hexobarbital (25 mg/kg) was determined 5 and 50 min after i.a. administered SP-sulphate (50 mg/kg), and decreased from 343 +/- 18 to 220 +/- 36 ml/min/kg (p less than 0.05).

KW - Animals

KW - Bile

KW - Bile Ducts

KW - Carotid Arteries

KW - Catheterization

KW - Chromatography, Gas

KW - Kinetics

KW - Male

KW - Portal Vein

KW - Rats

KW - Rats, Inbred Strains

KW - Sparteine

KW - Journal Article

M3 - Article

VL - 282

SP - 181

EP - 195

JO - Archives internationales de pharmacodynamie et de therapie

JF - Archives internationales de pharmacodynamie et de therapie

SN - 0003-9780

IS - 2

ER -